EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Voriconazole is inferior to amphotericin B deoxycholate as the initial induction therapy for HIV-associated Talaromyces marneffei fungemia: A multicenter retrospective study

Shasha Ye, Jiaying Qin, Xingguo Miao, Guanjing Lang, Mengyan Wang, Gong Chen, Feifei Su, Lijun Xu iD

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0013012 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Shasha Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Deoxycholic Acid, Talaromyces, Antifungal Agents, Amphotericin B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Chongqing Municipal Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal initial induction treatment for HIV-associated Talaromyces marneffei fungemia (HTMF) remains unclear.

Methods

Three hundred and fifteen patients with HIV-associated Talaromyces marneffei were enrolled in this multicenter retrospective study. The effectiveness of induction regimens with amphotericin B deoxycholate (iAmBd), voriconazole (iVori), and a switch regimen from iVori to AmBd (iVori→AmBd switch) on 180-day all-cause mortality in HTMF patients was assessed.

Results

The prevalence of HTMF was 75.9% (239/315) with a 180-day all-cause mortality of 20.1% (48/239). Among these HTMF patients, 44.4% (106/239) were treated with iAmBd, 41.8% (100/239) with iVori, and 13.8% (33/239) with other regimens. Additionally, 53% (53/100) of patients treated with iVori underwent an iVori→AmBd switch within 7 days. The 180-day cumulative survival rates were 88.7% for patients treated with iAmBd and 77.0% for those treated with iVori; 88.8% for patients who received AmBd within 3 days (iAmBd + 3-day iVori→AmBd switch) and 72.2% for those who continued iVori; 88.2% for patients who received AmBd within 5 days (iAmBd + 5-day iVori→AmBd switch) and 71.0% for those who continued iVori; 88.1% for those who received AmBd within 7 days (iAmBd + 7-day iVori→AmBd switch) and 66.0% for those who continued iVori (all log-rank P < 0.020). The prevalence of adverse drug reactions (ADRs) was 24.5% in the iAmBd group and 9.0% in the iVori group in induction stage (P < 0.001).

Conclusion

Voriconazole is inferior to AmBd as an initial induction therapy for HTMF patients. Early AmBd administration or an early iVori→AmBd switch improves survival, despite the higher incidence of AmBd-related ADRs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deoxycholic AcidTalaromycesAntifungal AgentsAmphotericin BVoriconazoleHIV InfectionsFungemiaHumansRetrospective StudiesMaleFemaleAdultMiddle AgedDrug CombinationsTreatment OutcomeAgedYoung Adult

Substanzen

Deoxycholic AcidAntifungal AgentsAmphotericin Bamphotericin B, deoxycholate drug combinationVoriconazoleDrug Combinations

Autor:innen und Institutionen

  • National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, Wenzhou, China.
  • Department II of Infectious Diseases, Xixi Hospital of Hangzhou, Zhejiang Chinese Medical University, Hangzhou, China.

ORCID-Profile: Lijun Xu

Förderung

  • National Key Research and Development Program of China
  • Chongqing Municipal Key Research and Development Program of China

Zitieren

APA

Ye, S., Qin, J., Miao, X., Lang, G., Wang, M., Chen, G., Su, F., & Xu, L. (2025). Voriconazole is inferior to amphotericin B deoxycholate as the initial induction therapy for HIV-associated Talaromyces marneffei fungemia: A multicenter retrospective study. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013012

Vancouver

Ye S, Qin J, Miao X, Lang G, Wang M, Chen G, et al. Voriconazole is inferior to amphotericin B deoxycholate as the initial induction therapy for HIV-associated Talaromyces marneffei fungemia: A multicenter retrospective study. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013012

BibTeX
@article{Ye2025,
  author = {Ye, Shasha and Qin, Jiaying and Miao, Xingguo and Lang, Guanjing and Wang, Mengyan and Chen, Gong and Su, Feifei and Xu, Lijun},
  title = {Voriconazole is inferior to amphotericin B deoxycholate as the initial induction therapy for HIV-associated Talaromyces marneffei fungemia: A multicenter retrospective study},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0013012}
}
Kostenlos starten →